0001638234-16-000002.txt : 20160506 0001638234-16-000002.hdr.sgml : 20160506 20160505204600 ACCESSION NUMBER: 0001638234-16-000002 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20160506 DATE AS OF CHANGE: 20160505 EFFECTIVENESS DATE: 20160506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Acer Therapeutics Inc. CENTRAL INDEX KEY: 0001638234 IRS NUMBER: 320426967 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-262700 FILM NUMBER: 161625675 BUSINESS ADDRESS: STREET 1: 222 THIRD STREET, SUITE 2240 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-922-3600 MAIL ADDRESS: STREET 1: 222 THIRD STREET, SUITE 2240 CITY: CAMBRIDGE STATE: MA ZIP: 02142 D 1 primary_doc.xml X0707 D LIVE 0001638234 Acer Therapeutics Inc. 222 THIRD STREET, SUITE 2240 CAMBRIDGE MA MASSACHUSETTS 02142 617-922-3600 DELAWARE None None Corporation true 2013 Christopher Schelling c/o Acer Therapeutics Inc. 222 Third Street, Suite 2240 Cambridge MA MASSACHUSETTS 02142 Executive Officer Director Promoter Cynthia Lavoie c/o Acer Therapeutics Inc. 222 Third Street, Suite 2240 Cambridge MA MASSACHUSETTS 02142 Director Stephen Aselage c/o Acer Therapeutics Inc. 222 Third Street, Suite 2240 Cambridge MA MASSACHUSETTS 02142 Director John Dunn c/o Acer Therapeutics Inc. 222 Third Street, Suite 2240 Cambridge MA MASSACHUSETTS 02142 Director Luc Marengere c/o Acer Therapeutics Inc. 222 Third Street, Suite 2240 Cambridge MA MASSACHUSETTS 02142 Director Harry S. Palmin c/o Acer Therapeutics Inc. 222 Third Street, Suite 2240 Cambridge MA MASSACHUSETTS 02142 Promoter Pharmaceuticals Decline to Disclose 06b false 2016-04-21 false true false 0 8149999 8149999 0 The exact Total Offering Amount and Total Amount Sold are $8,149,999.20 false 6 0 0 740000 true The Issuer expects to use approximately $740,000 of the proceeds for salary and other compensation to the Issuer's executive officers, directors and promoters during the 2016 fiscal year. false Acer Therapeutics Inc. /s/ Christopher Schelling Christopher Schelling President & CEO 2016-05-05